[ CAS No. 73874-95-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 73874-95-0 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	Inquiry	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ item.pr_usastock ]}		{[ item.pr_chinastock ]}	{[ item.pr_remark ]}	Login		Inquiry

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 73874-95-0 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 73874-95-0 ]

SDS Specification

Alternatived Products of [ 73874-95-0 ]

Product Citations

Design and synthesis of novel arylurea derivatives of aryloxy (1-phenylpropyl) alicyclic diamines with antimicrobial activity against multidrug-resistant Gram-positive bacteria

Canale, Vittorio ; Czekajewska, Joanna ; Klesiewicz, Karolina , et al. Eur. J. Med. Chem.,2023,251,115224. DOI: 10.1016/j.ejmech.2023.115224 PubMed ID: 36958177

Abstract: The alarming increase in the resistance of bacteria to the currently available antibiotics necessitates the development of new effective antimicrobial agents that are active against bacterial pathogens causing major public health problems. For this purpose, our inhouse libraries were screened against a wide panel of clin. relevant Gram-pos. and Gram-neg. bacteria, based on which compound I was selected for further optimization. Synthetic efforts in a group of arylurea derivatives of aryloxy(1-phenylpropyl) alicyclic diamines, followed with an in vitro evaluation of the activity against multidrug-resistant strains identified compound 44 (1-(3-chlorophenyl)-3-(1-{3-phenyl-3-[3-(trifluoromethyl)phenoxy] propyl}piperidin-4-yl)urea). Compound 44 showed antibacterial activity against Gram-pos. bacteria including fatal drug-resistant strains i.e., Staphylococcus aureus (methicillin-resistant, MRSA; vancomycin-intermediate, VISA) and Enterococcus faecium (vancomycin-resistant, VREfm) at low concentrations (0.78-3.125 μg/mL) comparable to last resort antibiotics (i.e., vancomycin and linezolid). It is also potent against biofilm-forming S. aureus and Staphylococcus epidermidis (including linezolid-resistant, LRSE) strains, but with no activity against Gram-neg. bacteria (Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa). Compound 44 showed strong bactericidal properties against susceptible and drug-resistant Gram-pos. bacteria. Depolarization of the bacterial cytoplasmic membrane induced by compound 44 suggests a dissipation of the bacterial membrane potential as its mechanism of antibacterial action. The high antimicrobial activity of compound 44, along with its selectivity over mammalian cells (lung MCR-5 and skin BJ fibroblast cell lines) and no hemolytic properties toward horse erythrocytes, proposes arylurea derivatives of aryloxy(1-phenylpropyl) alicyclic diamines for development of novel antibacterial agents.

Keywords: Arylurea derivatives ; Antibacterial properties ; Anti-MRSA activity ; Anti-VRE activity ; Anti-LRSE activity ; Depolarization of bacterial cell membrane

Purchased from AmBeed: 122536-76-9 ; 936-59-4 ; 135632-53-0 ; 404-71-7 ; 73874-95-0 ; 372-20-3 ; 98-17-9 ; 402-45-9 ; 57260-71-6 ; 122536-77-0 ; 444-30-4 ; 165800-03-3 ; 150-19-6 ; 1195-45-5 ; 2909-38-8 ; 165800-03-3 ...More

Product Details of [ 73874-95-0 ]

CAS No. :	73874-95-0	MDL No. :	MFCD00798171
Formula :	C₁₀H₂₀N₂O₂	Boiling Point :	-
Linear Structure Formula :	NHC₅H₉NHCOOC(CH₃)₃	InChI Key :	CKXZPVPIDOJLLM-UHFFFAOYSA-N
M.W :	200.28	Pubchem ID :	723833
Synonyms :		Chemical Name :	tert-Butyl piperidin-4-ylcarbamate

Calculated chemistry of [ 73874-95-0 ] Expand+

Physicochemical Properties

Num. heavy atoms :	14
Num. arom. heavy atoms :	0
Fraction Csp3 :	0.9
Num. rotatable bonds :	4
Num. H-bond acceptors :	3.0
Num. H-bond donors :	2.0
Molar Refractivity :	59.3
TPSA :	50.36 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.78 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.5
Log Po/w (XLOGP3) :	1.05
Log Po/w (WLOGP) :	0.88
Log Po/w (MLOGP) :	0.86
Log Po/w (SILICOS-IT) :	0.83
Consensus Log Po/w :	1.22

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.48
Solubility :	6.64 mg/ml ; 0.0332 mol/l
Class :	Very soluble
Log S (Ali) :	-1.7
Solubility :	4.01 mg/ml ; 0.02 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-2.05
Solubility :	1.8 mg/ml ; 0.00899 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.1

Safety of [ 73874-95-0 ]

Signal Word:	Danger	Class:	N/A
Precautionary Statements:	P280-P301+P312+P330-P302+P352-P305+P351+P338+P310	UN#:	N/A
Hazard Statements:	H302-H315-H318-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 73874-95-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 73874-95-0 ]
Downstream synthetic route of [ 73874-95-0 ]

[ 73874-95-0 ] Synthesis Path-Upstream 1~2

1
[ 73874-95-0 ]
[ 160357-94-8 ]

Reference： [1] Patent: WO2018/167276, 2018, A1,

2
[ 124-63-0 ]
[ 73874-95-0 ]
[ 287953-38-2 ]

Yield	Reaction Conditions	Operation in experiment
91%	at 20℃; for 16 h; Cooling with ice	5.00 g (25.0 mmol) of BOC-4-aminopiperidine are dissolved in pyridine (19.8 mL) and cooled in an ice bath. 2.13 mL (27.5 mmol) of methanesulfonyl chloride are added slowly. The reaction is stirred at RT for 16 h. After diluting with water, the reaction is extracted with DCM. Organic layers are washed with water, dried with MgS0₄ and filtered. The solvent is removed under reduced pressure to afford 6.30 g of (1 -Methanesulfonyl-piperidin-4-yl)-carbamic acid tert-butyl ester. Yield: 91 percent; ESI-MS: 279 [M+H]⁺
89%	With triethylamine In dichloromethane at 20℃; for 1 h;	EXAMPLE 4; Preparation of 4-(2-chloro-6-fluoro-benzoylamino)- 1 H-pyrazole-3 -carboxylic acid ( 1 -methanesulphonyl-piperidin-4-yl)-amide4A. 4-Amino-1H-pyrazole-3-carboxylic acid (l-methanesulphonyl-piperidin-4-yl) amideTo a stirred solution of 4-(N-BOC amino)piperidine (2.5 g, 12.5 mmoles) in dichloromethane (30 ml) was added triethylamine (2.1 ml, 15.0 mmoles), and then EPO <DP n="165"/>dropwise methanesulphonyl chloride (1.06 ml, 13.8 mmoles). The solution formed was stirred at room temperature for one hour. The reaction mixture was partitioned between EtOAc and water. The organic portion was washed with water, 2N HCl, brine, dried (MgSO₄) filtered and evaporated in vacuo to give 4-(N-BOC-amino)-l- methanesulphonylpiperidine as a white solid (3.1g, 89percent).
55%	With triethylamine In dichloromethane at 20℃; for 4 h;	General procedure: To a stirred solution of 2 (0.20 g, 1.00 mmol) in anhydrous DCM(5 mL) was added Et3N (0.42 mL, 3.00 mmol) at room temperature.Then 3a–i (3.96 mmol) was added in small portions at room temperature.The reaction was stirred for 4 h at this temperature and then quenched the reaction with saturated aqueous solution ofNaHCO3. The aqueous layer was extracted with ethyl acetate(3 10 mL). The combined organic layers were dried over anhydrousNa2SO4, filtered, and concentrated. Silica gel flash columnchromatography (EtOAc/hexanes = 1:2) of the residue gave 4a–ias the product. Dissolved 4a–i (0.34 g, 0.97 mmol) in 25 mL TFAat room temperature, the reaction was stirred at room temperature for 10 h. Distilled the TFA under vacuum and then diluted with saturated aqueous solution of NaHCO3. The aqueous layer wasextracted with ethyl acetate (3 10 mL). The combined organiclayers were dried over anhydrous Na2SO4, filtered, and concentrated.Silica gel flash column chromatography (EtOAc/hexanes =1:1) of the residue gave 5a–i as the product.

Reference： [1] Patent: WO2014/184327, 2014, A1, . Location in patent: Page/Page column 27
[2] Patent: WO2006/77414, 2006, A1, . Location in patent: Page/Page column 163-164
[3] Bioorganic Chemistry, 2015, vol. 61, p. 21 - 27
[4] Journal of Medicinal Chemistry, 2006, vol. 49, # 22, p. 6549 - 6560
[5] Patent: US2006/14708, 2006, A1, . Location in patent: Page/Page column 13
[6] Patent: EP2261213, 2010, A1, . Location in patent: Page/Page column 44-45

[ 73874-95-0 ] Synthesis Path-Downstream 1~7

1
[ 1005-38-5 ]
[ 73874-95-0 ]
[ 848498-96-4 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In 1-methyl-pyrrolidin-2-one; at 150℃; for 1.5h;Microwave;	TEA (0.243 ML, 1.74 mmol) and 6-CHLORO-2-(METHYLTHIO) pyrimidin-4-amine (0.309 g, 1.74 mmol) were added to a solution of tert-butyl piperidin-4-ylcarbamate (0.35 g, 1.74 mmol) in NMP (4 ML). Using a Smith Microwave Synthesizer, the mixture was subjected to single- mode microwave at 150 °C for 90 minutes. The mixture was partitioned between water and EtOAc and washed (x2) with water. The organic phase was dried over magnesium sulphate and concentrated to give the title compound (0.294 g). MS (ES) (MH+) : 340 for CL6H26N402S

Reference： [1]Patent: WO2005/26149,2005,A1 .Location in patent: Page/Page column 87

2
[ 73874-95-0 ]
[ 175205-81-9 ]
[ 898271-32-4 ]

Yield	Reaction Conditions	Operation in experiment
71%	With triethylamine; In dimethyl sulfoxide; at 120℃; for 17h;	tert-Butyl {l-[4-(trifluoromethyl)pyridin-2-yl]piperidin"4-yl}carbamate; A solution of <strong>[175205-81-9]2-bromo-4-trifluoromethylpyridine</strong> (1.0Og, 4.42mmol), tert-butyl piperidine-4- ylcarbamate (0.93g, 4.65mmol) and TEA (0.67mL, 4.86mmol) in DMSO (5mL) was heated at 1200C for 17h. The reaction mixture was evaporated to dryness, Et2O was added, and the organic phase was washed with water, brine and evaporated to dryness. The residue was purified using the Biotage Horizon HRFC system eluting with 22percent EtOAc in petroleum ether EPO <DP n="195"/>(40-60°C) to give the title compound (1.08g, 71percent) as a solid. 1H NMR(500MHz, CDCl3): 8.30 (d, IH), 6.82 (s, IH), 6.77 (d, IH), 4.49 (bs, IH), 4.36-4.22 (m, 2H), 3.74 (bs, IH), 3.06 (td, 2H), 2.10-2.04 (m, 2H), 1.56-1.38 (m, 11H); 13C NMR(CDCl3): 159.4, 155.4, 149.5, 140.1, 139.9, 124.5,122.4, 108.1, 102.7, 79.8, 48.3, 44.4, 32.3, 28.6; Mass Spectrum: M+H 5 346.

Reference： [1]Patent: WO2006/73366,2006,A1 .Location in patent: Page/Page column 193-194

3
[ 907545-47-5 ]
[ 73874-95-0 ]
[ 1051383-19-7 ]

Yield	Reaction Conditions	Operation in experiment
58%	With triethylamine; In tetrahydrofuran; at 50℃; for 2h;	Reference Example 35 2-{4-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-5-nitropyridine-4-carboxylic acid [Show Image] A solution of <strong>[907545-47-5]2-chloro-5-nitropyridine-4-carboxylic acid</strong> (1.50 g, 7.41 mmol), tert-butyl piperidin-4-ylcarbamate (1.48 g, 7.41 mmol) and triethylamine (3.1 mL, 22.2 mmol) in THF (19 mL) was stirred with heating at 50°C for 2 hr. After completion of the reaction, the mixture was neutralized with 1N hydrochloric acid, and extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (ethyl acetate:hexane=4:1 to 1:0) to give the title compound (1.57 g, yield 58percent) as a powder. EI(pos) 311.1 [M+H-tBu]+

Reference： [1]Patent: EP2123652,2009,A1 .Location in patent: Page/Page column 55

4
[ 64835-30-9 ]
[ 73874-95-0 ]
[ 1414968-15-2 ]

Yield	Reaction Conditions	Operation in experiment
84%	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20.0℃; for 1.0h;Inert atmosphere;	Diisopropylethylamine (1.74 ml, 9.98 mmol) was added in one portion to a stirred solution of piperidin-4-yl-carbamic acid tert-butyl ester (0.25 g, 1.25 mmol) in DCM (5 ml) at room temperature.To this mixture was added <strong>[64835-30-9]3-chloro-4-nitrobenzene sulfonyl chloride</strong> (0.32 g, 1.25 mmol) in one portion and the mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour.After this time the mixture was diluted with DCM (100 ml) and washed sequentially with HCl (1M solution, 50 ml), NaOH (1M solution, 50 ml) and brine (50 ml), the organic layer was separated, dried (MgSO4), filtered and concentrated.The resulting residue was purified by flash column chromatography (elution: percent EtOAc: percent Heptane) to give the title compound (0.44 g, 84percent yield) as a white solid. deltaH (500 MHz, DMSO) 7.97-8.12 (m, 3H) 6.93 (d, J=7.72 Hz, 1H) 3.64 (d, J=12.77 Hz, 2H) 3.43 (d, J=3.94 Hz, 2H) 2.88-3.00 (m, 2H) 1.78 (d, J=10.40 Hz, 2H) 1.25-1.46 (m, 11H). Tr=2.22 min, m/z (ES+) (M+Na)+ 442.

Reference： [1]Patent: US2012/302539,2012,A1 .Location in patent: Page/Page column 104

5
[ 3034-48-8 ]
[ 73874-95-0 ]
[ 1624309-39-2 ]

Yield	Reaction Conditions	Operation in experiment
84%	With potassium carbonate; In acetonitrile; at 20℃; for 4h;	4-N-Boc-aminopiperidine (0.96 g, 4.78 mmol) was added lot wise to a well stirred suspension of 2-bromo-5-nitro thiazole (1 g, 4.78 mmol) and potassium carbonate (0.79 g, 5.74 mmol) in acetonitrile (15 mL). The reaction mixture was then stirred at room temperature for about 4 h (monitored by TLC & LCMS for completion), and solvent evaporated under reduced pressure. The residue was further diluted with water (10 mL) and ethyl acetate (20 mL) and the layers separated. The aqueous layer was re-extracted with ethyl acetate (2 * 15 mL) and the combined organic layer was washed with brine (15 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure and the residue purified by column chromatography using hexane/ethylacetate as eluent to give the desired product 2 (1.32 g, 84percent) as yellow solid. 1H NMR (DMSO-d6): deltaH 1.39 (s, 9H), 1.44-4.03 (m, 9H), 8.38 (s, 1H), 13C NMR (DMSO-d6): deltac 171.9, 154.8, 147.6, 135.7, 77.8, 47.1, 46.1, 30.7, 28.2. ESI-MS m/z 329.1 (M+H)+. Anal. Calcd for C13H20N4O4S: C, 47.55; H, 6.14; N, 17.06. Found: C, 47.52; H, 6.11; N, 17.09.

Reference： [1]ChemMedChem,2014,vol. 9,p. 1850 - 1859
[2]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 588 - 601

6
[ 34584-69-5 ]
[ 73874-95-0 ]
tert-butyl (1-(6-chloro-4,5-dimethylpyridazin-3-yl)piperidin-4-yl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
80%	With potassium carbonate; In N,N-dimethyl-formamide; at 110℃; for 7h;Inert atmosphere;	General procedure: Solid K2CO3 (2 equiv) was added to a solution of <strong>[34584-69-5]3,6-dichloro-4,5-dimethylpyridazine</strong> (1 equiv) and amine (1 equiv) in DMF(20 mL), and the resulting solution was stirred at 110 °C for 7 h.The reaction mixture was concentrated under reduced pressure and dissolved in EtOAc, washed with water, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purifiedby silica gel column chromatography (ethyl acetate: hexane= 4:1) to yield pure product

Reference： [1]Bioorganic and Medicinal Chemistry,2018,vol. 26,p. 3308 - 3320

7
[ 454-16-0 ]
[ 73874-95-0 ]
tert-butyl (1-(2-methoxy-4-nitrophenyl)piperidin-4-yl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In N,N-dimethyl acetamide; at 120℃;	tert- Butyl piperidin-4-ylcarbamate (commercial, 500 mg, 3.22 mmol) was dissolved in DMA (10 ml_) and <strong>[454-16-0]1-fluoro-2-methoxy-4-nitrobenzene</strong> (552 mg, 3.22 mmol) was added followed by potassium carbonate (2.23 g, 16.1 mmol). The suspension was heated to 120C and stirred overnight before cooling and diluting with EtOAc. The organic phase was washed with 1 x water and 3 x 50% saturated brine solution and subsequently dried (anh. MgS04) and concentrated in vacuo to give the crude product (1.1 g, 78%) as an orange solid which was taken on as such into the next step. LCMS (Method B): RT = 1.45 min, m/z = 352 [M+H]+.

Reference： [1]Patent: WO2019/138227,2019,A1 .Location in patent: Page/Page column 59; 86-87

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

• Acyl Group Substitution • Buchwald-Hartwig C-N Bond and C-O Bond Formation Reactions • Chan-Lam Coupling Reaction • Complex Metal Hydride Reductions • Hydride Reductions • Lawesson's Reagent • Leuckart-Wallach Reaction • Mannich Reaction • Petasis Reaction • Preparation of Amines • Reactions of Amines • Specialized Acylation Reagents-Carbodiimides and Related Reagents • Specialized Acylation Reagents-Ketenes • Specialized Acylation Reagents-Vilsmeier Reagent • Ugi Reaction

Historical Records

Related Functional Groups of
[ 73874-95-0 ]

Amides

[ 287114-25-4 ]

tert-Butyl 8-azabicyclo[3.2.1]octan-3-ylcarbamate

Similarity: 0.98

[ 179110-74-8 ]

tert-Butyl piperidin-4-ylcarbamate hydrochloride

Similarity: 0.98

[ 163271-08-7 ]

tert-Butyl (4-methylpiperidin-4-yl)carbamate

Similarity: 0.96

[ 1298101-47-9 ]

tert-Butyl ((1S,3R)-3-aminocyclohexyl)carbamate

Similarity: 0.95

[ 645400-44-8 ]

tert-Butyl ((1S,3S)-3-aminocyclopentyl)carbamate

Similarity: 0.93

Amines

[ 287114-25-4 ]

tert-Butyl 8-azabicyclo[3.2.1]octan-3-ylcarbamate

Similarity: 0.98

[ 179110-74-8 ]

tert-Butyl piperidin-4-ylcarbamate hydrochloride

Similarity: 0.98

[ 163271-08-7 ]

tert-Butyl (4-methylpiperidin-4-yl)carbamate

Similarity: 0.96

[ 1298101-47-9 ]

tert-Butyl ((1S,3R)-3-aminocyclohexyl)carbamate

Similarity: 0.95

[ 645400-44-8 ]

tert-Butyl ((1S,3S)-3-aminocyclopentyl)carbamate

Similarity: 0.93

Related Parent Nucleus of
[ 73874-95-0 ]

Aliphatic Heterocycles

[ 287114-25-4 ]

tert-Butyl 8-azabicyclo[3.2.1]octan-3-ylcarbamate

Similarity: 0.98

[ 179110-74-8 ]

tert-Butyl piperidin-4-ylcarbamate hydrochloride

Similarity: 0.98

[ 163271-08-7 ]

tert-Butyl (4-methylpiperidin-4-yl)carbamate

Similarity: 0.96

[ 147539-41-1 ]

tert-Butyl 4-(methylamino)piperidine-1-carboxylate

Similarity: 0.91

[ 301225-58-1 ]

tert-Butyl 4-(propylamino)piperidine-1-carboxylate

Similarity: 0.91

Piperidines

[ 179110-74-8 ]

tert-Butyl piperidin-4-ylcarbamate hydrochloride

Similarity: 0.98

[ 163271-08-7 ]

tert-Butyl (4-methylpiperidin-4-yl)carbamate

Similarity: 0.96

[ 147539-41-1 ]

tert-Butyl 4-(methylamino)piperidine-1-carboxylate

Similarity: 0.91

[ 301225-58-1 ]

tert-Butyl 4-(propylamino)piperidine-1-carboxylate

Similarity: 0.91

[ 108612-54-0 ]

tert-Butyl methyl(piperidin-4-yl)carbamate

Similarity: 0.91

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 73874-95-0 ] {[proInfo.proName]}

Quality Control of [ 73874-95-0 ]

Related Doc. of [ 73874-95-0 ]

Product Citations

Product Details of [ 73874-95-0 ]

Calculated chemistry of [ 73874-95-0 ] Expand+

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 73874-95-0 ]

Application In Synthesis of [ 73874-95-0 ]

[ 73874-95-0 ] Synthesis Path-Upstream 1~2

[ 73874-95-0 ] Synthesis Path-Downstream 1~7

Technical Information

Related Functional Groups of [ 73874-95-0 ]

Amides

Amines

Related Parent Nucleus of [ 73874-95-0 ]

Aliphatic Heterocycles

Piperidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 73874-95-0 ]

Related Parent Nucleus of
[ 73874-95-0 ]